BioSpace News Archive

Cybin Inc. today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”).

Soligenix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial entitled, “Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behçet’s Disease.”

EDAP TMS SA, the global leader in robotic energy-based therapies, announced that is has received the Industry Category Award from the French National Institute for Intellectual Property based on the Company’s innovative therapeutic ultrasound technology.

TFF Pharmaceuticals, Inc. today announced the appointment of Michael Patane, Ph.D., to its Board of Directors.

TFF Pharmaceuticals, Inc. today announced that Catherine Lee, J.D. has been appointed to its Board of Directors.

BioAtla, Inc. today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023.

Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).

Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors.

Swedish Orphan Biovitrum AB has, as previously announced, carried out a share issue of series C shares, which has resulted in changes in the number of shares and votes in Sobi.

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, announces the appointment of Eliot Forster as CEO.